Acquired von Willebrand syndrome is an established cause of bleeding in persons with myeloproliferative diseases, accounting for approximately 12%-15% of all patients with this syndrome. von Willebrand syndrome is largely related to the absorption of von Willebrand factor onto the platelets; reducing the platelet count should alleviate the bleeding from the syndrome.
PV has no sex predilection, although the Polycythemia Vera Study Group (PVSG) found that slightly more males than females are affected. The peak incidence of PV is in individuals aged 50-70 years. However, this condition occurs in persons of all age groups, including early adulthood and childhood, albeit rarely.
Hyperhomocystinemia is a risk factor for thrombosis and is also widely prevalent in patients with myeloproliferative diseases.
For more on the etiology and epidemiology of PV, read here.
Medscape © 2018 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Emmanuel C. Besa. Fast Five Quiz: Are You Familiar With Key Aspects of Polycythemia Vera? - Medscape - Apr 04, 2018.